CN114002426A - 猪瘟病毒e0蛋白抗体elisa检测试剂盒 - Google Patents
猪瘟病毒e0蛋白抗体elisa检测试剂盒 Download PDFInfo
- Publication number
- CN114002426A CN114002426A CN202111265613.4A CN202111265613A CN114002426A CN 114002426 A CN114002426 A CN 114002426A CN 202111265613 A CN202111265613 A CN 202111265613A CN 114002426 A CN114002426 A CN 114002426A
- Authority
- CN
- China
- Prior art keywords
- kit
- protein
- antibody
- elisa detection
- hog cholera
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 61
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 52
- 241000710777 Classical swine fever virus Species 0.000 title claims abstract description 49
- 238000002965 ELISA Methods 0.000 title claims abstract description 39
- 238000001514 detection method Methods 0.000 title claims abstract description 33
- 102000036639 antigens Human genes 0.000 claims abstract description 18
- 108091007433 antigens Proteins 0.000 claims abstract description 18
- 239000011248 coating agent Substances 0.000 claims description 34
- 238000000576 coating method Methods 0.000 claims description 34
- 238000010790 dilution Methods 0.000 claims description 25
- 239000012895 dilution Substances 0.000 claims description 25
- 102000004190 Enzymes Human genes 0.000 claims description 24
- 108090000790 Enzymes Proteins 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 18
- 235000020183 skimmed milk Nutrition 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 17
- 239000003085 diluting agent Substances 0.000 claims description 14
- 238000007789 sealing Methods 0.000 claims description 11
- 239000013642 negative control Substances 0.000 claims description 9
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 5
- 241000283707 Capra Species 0.000 claims description 5
- 238000011161 development Methods 0.000 claims description 5
- 239000013641 positive control Substances 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 3
- 239000012089 stop solution Substances 0.000 claims description 3
- 150000001413 amino acids Chemical group 0.000 claims description 2
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 claims 5
- 239000006193 liquid solution Substances 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 abstract description 18
- 206010037660 Pyrexia Diseases 0.000 abstract description 8
- 238000000746 purification Methods 0.000 abstract description 7
- 229960005486 vaccine Drugs 0.000 abstract description 7
- 241000700605 Viruses Species 0.000 abstract description 4
- 238000010353 genetic engineering Methods 0.000 abstract description 4
- 244000144980 herd Species 0.000 abstract description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 20
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 19
- 238000011534 incubation Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 10
- 239000012528 membrane Substances 0.000 description 9
- 238000007865 diluting Methods 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 239000002033 PVDF binder Substances 0.000 description 5
- 241000282887 Suidae Species 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 5
- 239000012474 protein marker Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 208000001726 Classical Swine Fever Diseases 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 235000013861 fat-free Nutrition 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 235000003913 Coccoloba uvifera Nutrition 0.000 description 2
- 240000008976 Pterocarpus marsupium Species 0.000 description 2
- OYTNZCBFDXGQGE-XQXXSGGOSA-N Thr-Gln-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)O)N)O OYTNZCBFDXGQGE-XQXXSGGOSA-N 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- QDRGPQWIVZNJQD-CIUDSAMLSA-N Ala-Arg-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O QDRGPQWIVZNJQD-CIUDSAMLSA-N 0.000 description 1
- YNOCMHZSWJMGBB-GCJQMDKQSA-N Ala-Thr-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O YNOCMHZSWJMGBB-GCJQMDKQSA-N 0.000 description 1
- AENHOIXXHKNIQL-AUTRQRHGSA-N Ala-Tyr-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H]([NH3+])C)CC1=CC=C(O)C=C1 AENHOIXXHKNIQL-AUTRQRHGSA-N 0.000 description 1
- DPXDVGDLWJYZBH-GUBZILKMSA-N Arg-Asn-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O DPXDVGDLWJYZBH-GUBZILKMSA-N 0.000 description 1
- VNFWDYWTSHFRRG-SRVKXCTJSA-N Arg-Gln-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O VNFWDYWTSHFRRG-SRVKXCTJSA-N 0.000 description 1
- NKNILFJYKKHBKE-WPRPVWTQSA-N Arg-Gly-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O NKNILFJYKKHBKE-WPRPVWTQSA-N 0.000 description 1
- JOTRDIXZHNQYGP-DCAQKATOSA-N Arg-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N JOTRDIXZHNQYGP-DCAQKATOSA-N 0.000 description 1
- QLSRIZIDQXDQHK-RCWTZXSCSA-N Arg-Val-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QLSRIZIDQXDQHK-RCWTZXSCSA-N 0.000 description 1
- POOCJCRBHHMAOS-FXQIFTODSA-N Asn-Arg-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O POOCJCRBHHMAOS-FXQIFTODSA-N 0.000 description 1
- PBSQFBAJKPLRJY-BYULHYEWSA-N Asn-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N PBSQFBAJKPLRJY-BYULHYEWSA-N 0.000 description 1
- DJIMLSXHXKWADV-CIUDSAMLSA-N Asn-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O DJIMLSXHXKWADV-CIUDSAMLSA-N 0.000 description 1
- XEGZSHSPQNDNRH-JRQIVUDYSA-N Asn-Tyr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XEGZSHSPQNDNRH-JRQIVUDYSA-N 0.000 description 1
- PQKSVQSMTHPRIB-ZKWXMUAHSA-N Asn-Val-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O PQKSVQSMTHPRIB-ZKWXMUAHSA-N 0.000 description 1
- WSWYMRLTJVKRCE-ZLUOBGJFSA-N Asp-Ala-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O WSWYMRLTJVKRCE-ZLUOBGJFSA-N 0.000 description 1
- GWTLRDMPMJCNMH-WHFBIAKZSA-N Asp-Asn-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O GWTLRDMPMJCNMH-WHFBIAKZSA-N 0.000 description 1
- JNNVNVRBYUJYGS-CIUDSAMLSA-N Asp-Leu-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O JNNVNVRBYUJYGS-CIUDSAMLSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- RRIJEABIXPKSGP-FXQIFTODSA-N Cys-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CS RRIJEABIXPKSGP-FXQIFTODSA-N 0.000 description 1
- LWTTURISBKEVAC-CIUDSAMLSA-N Cys-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)N LWTTURISBKEVAC-CIUDSAMLSA-N 0.000 description 1
- KGIHMGPYGXBYJJ-SRVKXCTJSA-N Cys-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CS KGIHMGPYGXBYJJ-SRVKXCTJSA-N 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- QQAPDATZKKTBIY-YUMQZZPRSA-N Gln-Gly-Met Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O QQAPDATZKKTBIY-YUMQZZPRSA-N 0.000 description 1
- BVELAHPZLYLZDJ-HGNGGELXSA-N Gln-His-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(O)=O BVELAHPZLYLZDJ-HGNGGELXSA-N 0.000 description 1
- AFODTOLGSZQDSL-PEFMBERDSA-N Glu-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N AFODTOLGSZQDSL-PEFMBERDSA-N 0.000 description 1
- ZZIFPJZQHRJERU-WDSKDSINSA-N Glu-Cys-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O ZZIFPJZQHRJERU-WDSKDSINSA-N 0.000 description 1
- OPAINBJQDQTGJY-JGVFFNPUSA-N Glu-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCC(=O)O)N)C(=O)O OPAINBJQDQTGJY-JGVFFNPUSA-N 0.000 description 1
- HPJLZFTUUJKWAJ-JHEQGTHGSA-N Glu-Gly-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HPJLZFTUUJKWAJ-JHEQGTHGSA-N 0.000 description 1
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 1
- LLXVQPKEQQCISF-YUMQZZPRSA-N Gly-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CN LLXVQPKEQQCISF-YUMQZZPRSA-N 0.000 description 1
- CLNSYANKYVMZNM-UWVGGRQHSA-N Gly-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N CLNSYANKYVMZNM-UWVGGRQHSA-N 0.000 description 1
- CUVBTVWFVIIDOC-YEPSODPASA-N Gly-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CN CUVBTVWFVIIDOC-YEPSODPASA-N 0.000 description 1
- DGYNAJNQMBFYIF-SZMVWBNQSA-N His-Glu-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CN=CN1 DGYNAJNQMBFYIF-SZMVWBNQSA-N 0.000 description 1
- PGTISAJTWZPFGN-PEXQALLHSA-N His-Gly-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O PGTISAJTWZPFGN-PEXQALLHSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- QIHJTGSVGIPHIW-QSFUFRPTSA-N Ile-Asn-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N QIHJTGSVGIPHIW-QSFUFRPTSA-N 0.000 description 1
- NPROWIBAWYMPAZ-GUDRVLHUSA-N Ile-Asp-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N NPROWIBAWYMPAZ-GUDRVLHUSA-N 0.000 description 1
- BEWFWZRGBDVXRP-PEFMBERDSA-N Ile-Glu-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O BEWFWZRGBDVXRP-PEFMBERDSA-N 0.000 description 1
- SPQWWEZBHXHUJN-KBIXCLLPSA-N Ile-Glu-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O SPQWWEZBHXHUJN-KBIXCLLPSA-N 0.000 description 1
- UAQSZXGJGLHMNV-XEGUGMAKSA-N Ile-Gly-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N UAQSZXGJGLHMNV-XEGUGMAKSA-N 0.000 description 1
- MITYXXNZSZLHGG-OBAATPRFSA-N Ile-Trp-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)N MITYXXNZSZLHGG-OBAATPRFSA-N 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- VPKIQULSKFVCSM-SRVKXCTJSA-N Leu-Gln-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VPKIQULSKFVCSM-SRVKXCTJSA-N 0.000 description 1
- NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 description 1
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- VDIARPPNADFEAV-WEDXCCLWSA-N Leu-Thr-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O VDIARPPNADFEAV-WEDXCCLWSA-N 0.000 description 1
- YVSHZSUKQHNDHD-KKUMJFAQSA-N Lys-Asn-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N YVSHZSUKQHNDHD-KKUMJFAQSA-N 0.000 description 1
- LPAJOCKCPRZEAG-MNXVOIDGSA-N Lys-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCCN LPAJOCKCPRZEAG-MNXVOIDGSA-N 0.000 description 1
- HAUUXTXKJNVIFY-ONGXEEELSA-N Lys-Gly-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAUUXTXKJNVIFY-ONGXEEELSA-N 0.000 description 1
- VLMNBMFYRMGEMB-QWRGUYRKSA-N Lys-His-Gly Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CNC=N1 VLMNBMFYRMGEMB-QWRGUYRKSA-N 0.000 description 1
- XDPLZVNMYQOFQZ-BJDJZHNGSA-N Lys-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N XDPLZVNMYQOFQZ-BJDJZHNGSA-N 0.000 description 1
- UZVWDRPUTHXQAM-FXQIFTODSA-N Met-Asp-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O UZVWDRPUTHXQAM-FXQIFTODSA-N 0.000 description 1
- XPVCDCMPKCERFT-GUBZILKMSA-N Met-Ser-Arg Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O XPVCDCMPKCERFT-GUBZILKMSA-N 0.000 description 1
- FZDOBWIKRQORAC-ULQDDVLXSA-N Met-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCSC)N FZDOBWIKRQORAC-ULQDDVLXSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 description 1
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 1
- LUGOKRWYNMDGTD-FXQIFTODSA-N Pro-Cys-Asn Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O LUGOKRWYNMDGTD-FXQIFTODSA-N 0.000 description 1
- GBUNEGKQPSAMNK-QTKMDUPCSA-N Pro-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@@H]2CCCN2)O GBUNEGKQPSAMNK-QTKMDUPCSA-N 0.000 description 1
- GZNYIXWOIUFLGO-ZJDVBMNYSA-N Pro-Thr-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZNYIXWOIUFLGO-ZJDVBMNYSA-N 0.000 description 1
- IIRBTQHFVNGPMQ-AVGNSLFASA-N Pro-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1 IIRBTQHFVNGPMQ-AVGNSLFASA-N 0.000 description 1
- NQZFFLBPNDLTPO-DLOVCJGASA-N Ser-Phe-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CO)N NQZFFLBPNDLTPO-DLOVCJGASA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- FVFUOQIYDPAIJR-XIRDDKMYSA-N Ser-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CO)N FVFUOQIYDPAIJR-XIRDDKMYSA-N 0.000 description 1
- VIBXMCZWVUOZLA-OLHMAJIHSA-N Thr-Asn-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O VIBXMCZWVUOZLA-OLHMAJIHSA-N 0.000 description 1
- NRUPKQSXTJNQGD-XGEHTFHBSA-N Thr-Cys-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NRUPKQSXTJNQGD-XGEHTFHBSA-N 0.000 description 1
- DXNUZQGVOMCGNS-SWRJLBSHSA-N Thr-Gln-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O DXNUZQGVOMCGNS-SWRJLBSHSA-N 0.000 description 1
- IJVNLNRVDUTWDD-MEYUZBJRSA-N Thr-Leu-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IJVNLNRVDUTWDD-MEYUZBJRSA-N 0.000 description 1
- HDQJVXVRGJUDML-UBHSHLNASA-N Trp-Cys-Asn Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)N HDQJVXVRGJUDML-UBHSHLNASA-N 0.000 description 1
- AWEGFIJXYWGBCA-XIRDDKMYSA-N Trp-His-Asn Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](CC(=O)N)C(=O)O)N AWEGFIJXYWGBCA-XIRDDKMYSA-N 0.000 description 1
- OCCYDHCUKXRPSJ-SXNHZJKMSA-N Trp-Ile-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O OCCYDHCUKXRPSJ-SXNHZJKMSA-N 0.000 description 1
- ACGIVBXINJFALS-HKUYNNGSSA-N Trp-Phe-Gly Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N ACGIVBXINJFALS-HKUYNNGSSA-N 0.000 description 1
- WMIUTJPFHMMUGY-ZFWWWQNUSA-N Trp-Pro-Gly Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)NCC(=O)O WMIUTJPFHMMUGY-ZFWWWQNUSA-N 0.000 description 1
- JFDGVHXRCKEBAU-KKUMJFAQSA-N Tyr-Asp-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O JFDGVHXRCKEBAU-KKUMJFAQSA-N 0.000 description 1
- XBWKCYFGRXKWGO-SRVKXCTJSA-N Tyr-Cys-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O XBWKCYFGRXKWGO-SRVKXCTJSA-N 0.000 description 1
- XGJLNBNZNMVJRS-NRPADANISA-N Val-Glu-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O XGJLNBNZNMVJRS-NRPADANISA-N 0.000 description 1
- GBESYURLQOYWLU-LAEOZQHASA-N Val-Glu-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N GBESYURLQOYWLU-LAEOZQHASA-N 0.000 description 1
- ROLGIBMFNMZANA-GVXVVHGQSA-N Val-Glu-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N ROLGIBMFNMZANA-GVXVVHGQSA-N 0.000 description 1
- OFTXTCGQJXTNQS-XGEHTFHBSA-N Val-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N)O OFTXTCGQJXTNQS-XGEHTFHBSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010084758 arginyl-tyrosyl-aspartic acid Proteins 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108010085203 methionylmethionine Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了猪瘟病毒E0蛋白抗体ELISA检测试剂盒,属于病毒抗体检测技术领域。猪瘟病毒E0蛋白抗体ELISA检测试剂盒,包括CSFVE0蛋白抗原,CSFVE0蛋白抗原氨基酸序列如SEQ ID NO.1所示。本发明基于猪群免疫猪瘟E2基因工程疫苗能产生针对CSFVE2抗体但不产生E0抗体的特点提供猪瘟病毒E0蛋白抗体ELISA检测试剂盒,通过对E0抗体的鉴定可为猪瘟净化提供技术支持。
Description
技术领域
本发明属于病毒抗体检测技术领域,具体涉及猪瘟病毒E0蛋白抗体ELISA检测试剂盒。
背景技术
猪瘟(Classical Swine Fever,CSF)是由猪瘟病毒(Classical Swine FeverVirus,CSFV)引起的一种严重威胁生猪产业发展的烈性传染病。E2基因工程疫苗已经上市且广泛应用于猪场,市售的猪瘟病毒抗体检测试剂盒主要通过检测CSFV E2抗体来评估猪场疫苗免疫效果,鲜有用于CSF野毒感染猪筛查的抗体试剂盒。而由于目前普遍使用兔化弱毒疫苗来防控猪瘟,因此无法通过血清学方法区分免疫猪和感染猪,给猪瘟净化带来很大困难。
发明内容
本发明基于猪群免疫猪瘟E2基因工程疫苗能产生针对CSFV E2抗体但不产生E0抗体的特点提供了猪瘟病毒E0蛋白抗体ELISA检测试剂盒,通过对E0抗体的鉴定可为猪瘟净化提供技术支持。
为了实现上述目的,本发明采用如下技术方案:
猪瘟病毒E0蛋白抗体ELISA检测试剂盒,包括CSFV E0蛋白抗原,CSFV E0蛋白抗原氨基酸序列如SEQ ID NO.1所示:KALLAWAVIAIMLYQPVEAENITQWNLSDNGTNGIQHAMYLRGVNRSLHGIWPGKICKGVPTHLATDVELKEIQGMMDASEGTNYTCCKLQRHEWNKHGWCNWHNIDPWIQLMSRTQADLAEGPPVKECAVTCRYDKDADINVVTQARNRPTTLTGCKKGKNFSFAGTVIESPCNFNVSVEDTLYGDHECGSLLQDAALYLVDGMTNTIENARQGAARVTSWLGRQLSTAGKRLEGRSKTWFGAYALSPYCNVTSKIGYIWYTNNCT。
优选地,上述猪瘟病毒E0蛋白抗体ELISA检测试剂盒,还包括酶标板和包被液;
CSFV E0蛋白抗原经包被液稀释,包被于酶标板上。
优选地,包被液为50mM pH7.5的Tris盐酸盐缓冲液;
CSFV E0蛋白抗原经包被液稀释为2μg/mL,包被于酶标板上。
优选地,上述猪瘟病毒E0蛋白抗体ELISA检测试剂盒,还包括封闭液;
封闭液为质量分数10%的脱脂奶粉或质量分数1%的明胶,用于CSFV E0蛋白抗原包被后封闭。
优选地,上述猪瘟病毒E0蛋白抗体ELISA检测试剂盒,还包括一抗稀释液;
一抗稀释液为质量分数1%的脱脂奶粉,按1:200稀释样品。
优选地,上述猪瘟病毒E0蛋白抗体ELISA检测试剂盒,还包括酶标二抗和二抗稀释液;
酶标二抗为HRP标记山羊抗猪二抗;
二抗稀释液为质量分数5%的脱脂奶粉,按1:10000稀释酶标二抗。
优选地,上述猪瘟病毒E0蛋白抗体ELISA检测试剂盒,还包括显色液和终止液。
优选地,上述猪瘟病毒E0蛋白抗体ELISA检测试剂盒,还包括阴性对照和阳性对照。
综上所述,本发明试剂盒可用于免疫猪瘟E2基因工程疫苗的猪场进行猪瘟E0抗体检测,通过血清学检测就可以实现疫苗免疫猪和野毒感染猪的鉴别诊断,可操作性强,特异性好,重复性好,适于推广应用。
附图说明
图1所示为CSFV E0基因PCR结果;
其中,M:2000 DNA标准;1:阴性对照;2:CSFV E0基因;
图2所示为pET-32a-E0双酶切结果;
其中,M:5000DNA标准;1:pET-32a-E0;
图3所示为pET-32a-E0重组蛋白诱导不同时间的SDS-PAGE检测;
其中,M:蛋白MARKER;0-5:诱导0、1、2、3、4、5h的重组菌;
图4所示为pET-32a-E0重组蛋白可溶性的SDS-PAGE分析;
其中,M:蛋白MARKER;1:pET-32a空载体;2:可溶性上清;3:包涵体沉淀;
图5所示为pET-32a-E0重组蛋白纯化的SDS-PAGE分析;
其中,M:蛋白MARKER;1:pET-32a-E0重组蛋白2:pET-32a-E0重组纯化蛋白;
图6所示为pET-32a-E0重组蛋白的Western-blotting分析(小鼠抗His标签抗体);
其中,M:蛋白MARKER;1:pET-32a-E0重组蛋白2:pET-32a空载体蛋白;
图7所示为pET-32a-E0重组蛋白的Western-blotting分析(CSFV E0阳性猪血清);
其中,M:蛋白MARKER;1:pET-32a-E0重组蛋白2:pET-32a空载体蛋白;
图8所示为纯化重组蛋白标准曲线。
具体实施方式
下面对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。实施例中未公开的实验步骤按照试剂产品说明书进行。
实施例1 CSFV E0基因的原核表达
按照表1合成扩增CSFV E0基因的引物,其中上下游引物5’端分别加入保护性碱基和酶切位点(上游BamHⅠ,下游XhoⅠ),下划线为BamHⅠ和XhoⅠ酶切识别位点。
表1
选择与疫苗株HCLV(AF091507)和C-ZJ-2008(HM175885)同源性为82.5%-82.6%的2.1c毒株FJTB006(来源于福建),以其cDNA作为模板进行PCR扩增,扩增E0基因片段,PCR反应体系如表2,反应条件如表3,反应结束后用1%的琼脂糖凝胶电泳对PCR产物进行鉴定,如图1所示,得到与预期目的片段大小一致的条带。
表2
表3
将目的片段从琼脂糖凝胶上切下,置于1.5mL离心管中,使用南京诺唯赞生物科技股份有限公司的胶回收纯化试剂盒回收。
回收产物使用pEASY-Blunt E1 Expression Kit试剂(北京全式金生物技术有限公司)连接到pEASY上,获得重组质粒pEASY-E0,将pEASY-E0转化至DH5α感受态细胞(上海唯地生物技术有限公司)中。
使用质粒小提取试剂盒(天根生化科技(北京)有限公司)提取重组质粒,送往北京睿博兴科生物有限公司进行测序,得到的基因序列使用DNAStar软件与GenBank中相应的基因序列进行比较分析,经比较并未出现移位和突变等情况,确定目的基因成功构建于载体中。
测序正确的pEASY-E0与pET-32a原核达载体使用BamHⅠ和XhoⅠ酶切连接,构建pET-32a-E0;将pET-32a-E0用BamHⅠ和XhoⅠ双酶切,分别得到先行载体(约2900bp)和目的基因两条带(图2),说明重组质粒pET-32a-E0构建成功。
诱导表达:pET-32a-E0转化BL21感受态细胞(南京诺唯赞生物科技股份有限公司),扩大菌液培养,37℃200rpm震荡培养至OD600值在0.4-0.6之间,取1mL菌液于1.5mL离心管中,为0h样品。菌液中加1mmol/L的IPIG后,继续震荡培养并在1h、2h、3h、4h、5h时各取样1mL。离心去上清后,加入0.2倍体积的5×SDS-PAGE Loading Buffer,混匀后煮沸10min,往SDS-PAGE凝胶中每孔加入10μL蛋白样品,条件设置为电压80V电流30mA,待溴酚蓝指示条带跑出浓缩胶后,将电压条件更改为120V,电流不变。考马斯亮蓝染色看结果,选择最佳诱导时间。如图3所示,诱导时间为3-5h时,有预期大小相符的蛋白(45KD)大量表达。出于时间成本的考虑,选择3h为最佳诱导时间。
可溶性鉴定:扩大菌液培养,37℃200rpm震荡培养至OD600值在0.4-0.6之间,加入IPTG,继续培养5h。菌液反复冻融3次,离心去除上清,用PBS洗涤2次。加400μL PBS,于冰上300W超声3s,停5s,共10min左右。待菌液清亮不粘稠,离心分别收集沉淀和上清检测蛋白的表达形式。如图4所示,沉淀中的目的蛋白明显多于上清,说明其主要在包涵体中表达。
蛋白纯化:使用康为世纪的His标签蛋白纯化试剂盒(包涵体蛋白)进行蛋白纯化,纯化后,经SDS-PAGE鉴定发现(图5),仅在45kD左右存在单一条带,表明重组蛋白纯化效果良好。
将纯化后的蛋白经过SDS-PAGE电泳后使用湿转法进行Western Blot,步骤如下:
(1)将蛋白胶与PVDF膜按顺序摆放后放置于转膜电泳仪中,设置电流200mA,电泳2h。
(2)封闭:转膜结束后用5%脱脂奶粉封闭1h,取出PVDF膜用TBST清洗2次,每次5min。
(3)一抗[小鼠抗His标签抗体(cbcam)/CSFV E0阳性猪血清]孵育:在封闭好的PVDF膜中加入已用一抗稀释液(碧云天生物技术有限公司)稀释的一抗,放于4℃冰箱过夜,隔天使用TBST于室温洗脱3次,每次10min。
(4)二抗[HRP标记的山羊抗小鼠二抗(cbcam)/HRP标记的山羊抗猪二抗(cbcam)]孵育:在已孵育好一抗的PVDF膜加入经二抗稀释液(碧云天生物技术有限公司)稀释后的二抗,置于37℃摇床中孵育60分钟,弃去二抗,使用TBST洗脱3次,每次10分钟。
(5)吸取特超敏ECL化学发光试剂(碧云天生物技术有限公司)A、B液等比例混匀,将混合液加在PVDF膜上,避光放置10分钟后于荧光凝胶电泳呈像分析仪观看结果并拍照保存。
Western-blotting分析结果如图6、7所示,显色后在约45kD处可见一明显条带,重组蛋白能够被His标签抗体和CSFV E0阳性猪血清特异性识别,表明纯化后的蛋白具有良好的反应原性。
实施例2 CSFV E0重组蛋白间接ELISA检测方法的建立及检测
检测所用样品CSFVE0阴性血清、CSFV E0阳性血清和猪临床血清样品均由龙岩学院动物医学研究所保存。
1.重组蛋白最适稀释倍数和血清最佳稀释倍数的确定
将纯化后的pET-32a-E0重组蛋白稀释成不同浓度,利用上海碧云天生物技术有限公司的BCA蛋白浓度测定试剂盒(增强型)进行浓度测定。读取OD450nm值制作标准曲线,结果如表4、5,图8所示,公式为y=0.8208x+1.5499,R2=0.9203;检测蛋白样品的OD450nm值,可得蛋白浓度为0.218mg/mL。
表4
表5
利用方阵法,设置2个复孔,对重组蛋白最佳稀释倍数和血清最佳稀释倍数进行确定。根据所测定的蛋白浓度将蛋白稀释为8μg/mL,在前二列加入100μL浓度8μg/mL的蛋白,其余孔加入100μL蛋白稀释液,在96孔板上进行倍比稀释,稀释后最低浓度为0.25μg/mL。将CSFV E0阴、阳性血清按照1:50稀释,在前二行加入100μL稀释后的血清,其余孔加入100μL血清稀释液,在96孔板上进行倍比稀释,稀释后最大稀释倍数为1:400。二抗使用HRP标记山羊抗猪(cbcam),用酶标仪读OD450nm值后进行分析,选择最佳稀释倍数和血清最佳稀释倍数。结果如表6所示,当蛋白抗原包被浓度为2μg/mL、血清稀释度为1:200时,P/N值较大为11.332,且CSFV E0阳性血清OD450nm值接近1.0。
表6
注:+代表阳性血清OD450nm值;-表示阴性血清OD450nm值;加粗字体表示最佳反应条件下的阳性OD450nm值、阴性OD450nm值和P/N值。
2.抗原最适包被液的选择
使用最适蛋白浓度进行包被,一抗血清稀释到最佳浓度,对最适包被液进行筛选择磷酸盐缓冲液(10mM pH7.2)、Tris盐酸盐缓冲液(50mM pH7.5)和碳酸盐缓冲液(50mMpH9.6)作为蛋白稀释液进行蛋白包被。用酶标仪读OD450nm值后进行分析,选择抗原最佳包被液。
结果如表7,当pET-32a-E0重组蛋白使用Tris盐酸盐缓冲液(50mM pH7.5)包被时,P/N值明显大于其它组,包被效果最好。
表7
3.抗原最适包被时间的选择
使用最适条件进行蛋白包被,一抗血清稀释到最佳浓度,挑选最适包被时间。分别选择4℃包被12h、4℃包被10h、37℃包被1h、37℃包被2h和37℃包被2h、4℃包被2h。用酶标仪读OD450nm值后进行分析,选择抗原最佳包被时间。结果如表8所示,当重组蛋白在4℃包被12h时,P/N值大于其它组,包被效果最好。
表8
4.最适封闭液的选择
使用最适条件进行蛋白包被,一抗血清稀释到最佳浓度,对最适封闭液进行筛选。选择质量分数5%脱脂奶粉、10%脱脂奶粉、1%明胶、2%胎牛血清、1%BSA、3%BSA和5%BSA作为封闭液进行封闭。用酶标仪读OD450nm值后进行分析,选择最佳封闭液。结果如表9所示,当重组蛋白使用10%脱脂奶粉或1%明胶封闭时,P/N值大于其它组,封闭效果最好。后续实验以10%脱脂奶粉作为封闭液。
表9
5.最适封闭时间的选择
使用最适条件进行蛋白包被,一抗血清稀释到最佳浓度,挑选最适封闭时间。分别37℃封闭30min、60min、90min和120min。用酶标仪读OD450nm值后进行分析,选择最佳封闭时间。结果如表10所示,当重组蛋白在37℃封闭60min时,P/N值大于其它组,封闭效果最好。
表10
6.最适一抗血清稀释液的选择
使用最适条件进行蛋白包被,一抗血清稀释到最佳浓度,对最适一抗血清稀释液进行筛选。选择质量分数1%脱脂奶粉、5%脱脂奶粉、PBS、PBST、0.1%BSA、1%BSA、1%明胶和2%胎牛血清作为一抗血清稀释液进行孵育。用酶标仪读OD450nm值后进行分析,选择最适一抗血清稀释液。结果如表11所示,当使用质量分数1%脱脂奶粉稀释一抗血清时,P/N值明显大于其它组。
表11
7.最适一抗血清孵育时间的选择
使用最适条件进行蛋白包被和一抗血清的稀释和孵育,挑选最适一抗血清孵育时间。分别37℃孵育30min、60min、90min和120min。用酶标仪读OD450nm值后进行分析,选择最适一抗血清孵育时间。结果如表12所示,当质量分数1%脱脂奶粉稀释一抗血清,在37℃孵育90min时,P/N值大于其它组,孵育效果最好。
表12
8.最适酶标二抗稀释度的选择
使用最适条件进行蛋白包被和一抗血清的稀释和孵育,挑选最适酶标二抗稀释度。将酶标二抗分别稀释成1:2500、1:5000、1:10000、1:20000和1:40000进行孵育。用酶标仪读OD450nm值后进行分析,选择最适酶标二抗稀释度。结果如表13所示,当使用1:10000稀释的酶标二抗时,P/N值明显大于其它组。
表13
9.最适酶标二抗稀释液的选择
使用最适条件进行蛋白包被,一抗血清稀释到最佳浓度,对最适酶标二抗稀释液进行筛选。选择质量分数1%脱脂奶粉、5%脱脂奶粉、PBS、PBST、0.1%BSA、1%BSA、1%明胶和2%胎牛血清作为酶标二抗稀释液进行孵育。用酶标仪读OD450nm值后进行分析,选择最适酶标二抗稀释液。结果如表14所示,当使用5%脱脂奶粉稀释酶标二抗时,P/N值大于其它组。
表14
10.最适酶标二抗孵育时间的选择
使用最适条件进行蛋白包被和一抗血清的稀释和孵育,挑选最适酶标二抗孵育时间。分别37℃孵育30min、60min、90min和120min。用酶标仪读OD450nm值后进行分析,选择最适酶标二抗孵育时间。结果如表15所示,当酶标二抗37℃孵育90min时,P/N值大于其它组,孵育效果最好。
表15
11.间接ELISA方法步骤的确定
根据以上各条件的优化结果,确定了间接ELISA的操作程序:
(1)包被:将纯化后重组蛋白用Tris盐酸盐缓冲液(50mM pH7.5)稀释成2μg/mL,在96孔酶标板中加入100μL稀释好的抗原,4℃包被12h;用PBST洗涤4次,每次静置1min,拍干;
(2)封闭:每孔加300μL 10%脱脂奶粉封闭,37℃封闭60min;用PBST洗涤4次,每次静置1min,拍干;
(3)孵育一抗血清:1:200稀释样品,在稀释板中每孔加入199μL 1%脱脂奶粉,各孔加入1μL一抗血清样品和阳性、阴性对照,充分混匀;包被板加入阳性、阴性对照和样品各100μL(阳性、阴性对照设置复孔),37℃孵育90min;用PBST洗涤4次,每次静置1min,拍干;
(4)孵育酶标二抗:使用5%脱脂奶粉按1:10000稀释HRP标记山羊抗猪酶标二抗,每孔加100μL,37℃孵育90min。用PBST洗涤4次,每次静置1min,拍干;
(5)显色:加100μLTMB,37℃避光孵育10min;
(6)终止:加入100μL终止液停止反应,轻微震荡混合均匀;
(7)读数:预热酶标仪后,在450nm的波长下读取吸光度值(30min内测定)。
12.阴性极限值的测定
用上述优化的ELISA方法对30份用北京金诺CSFV E0蛋白ELISA检测试剂盒判定CSFV E0为阴性血清进行检测,用酶标仪读OD450nm值后进行计算分析。计算平均值(x)和标准差(S),根据统计学原理,OD450nm≤阴性对照标准方差(SD)×3+阴性对照平均值(x)时可判为阴性,否则,即判为阳性。
结果如表16所示,30份阴性血清OD450nm值的平均值(x)为0.195,标准差(SD)为0.055,根据阴性对照极限值等于3倍的标准差(SD)加上平均值(x),计算出阴性极限值为0.361,当样本OD450nm≤0.361时,判断为阴性,反之则判断为阳性。
表16
14.交叉反应试验
选择PRRSV(IDEXX试剂盒提供)、PRV(北京金诺试剂盒提供)、PCV 2(北京金诺试剂盒提供)、PEDV(IDVet试剂盒提供)、CSFV E0阳性血清和CSFV E0阴性血清进行交叉实验。结果如表17所示,除了CSFV E0阳性血清,其它血清样本的OD450nm值均小于阴性极限值。
表17
15.重复性试验
选择4份不同的猪血清样品,利用pET-32a-E0重组蛋白建立的优化的间接ELISA方法,在同一96孔反应板上和三块不同的96孔板上进行平行试验,用酶标仪读OD450nm值后计算批内/批间重复试验的变异系数来检验所建立ELISA方法的重复性。批内重复性试验结果如表18所示,平均变异系数为3.43%;批间重复试验结果如表19所示,平均变异系数为3.30%;表明建立的pET-32a-E0重组蛋白的间接ELISA方法有较好重复性。
表18
表19
根据上述实验可知,本发明建立的pET-32a-E0重组蛋白的间接ELISA方法特异性好,重复性好,可将相应试剂制备成试剂盒,便于推广应用。
本说明书中各个实施例采用递进的方式描述,每个实施例重点说明的都是与其他实施例的不同之处,各个实施例之间相同相似部分互相参见即可。
对所公开的实施例的上述说明,使本领域专业技术人员能够实现或使用本发明。对上述实施例的多种修改对本领域的专业技术人员来说将是显而易见的,本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下,在其它实施例中实现。因此,本发明将不会被限制于本文所示的这些实施例,而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
序列表
<110> 龙岩学院
<120> 猪瘟病毒E0蛋白抗体ELISA检测试剂盒
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 267
<212> PRT
<213> Artificial
<400> 1
Lys Ala Leu Leu Ala Trp Ala Val Ile Ala Ile Met Leu Tyr Gln Pro
1 5 10 15
Val Glu Ala Glu Asn Ile Thr Gln Trp Asn Leu Ser Asp Asn Gly Thr
20 25 30
Asn Gly Ile Gln His Ala Met Tyr Leu Arg Gly Val Asn Arg Ser Leu
35 40 45
His Gly Ile Trp Pro Gly Lys Ile Cys Lys Gly Val Pro Thr His Leu
50 55 60
Ala Thr Asp Val Glu Leu Lys Glu Ile Gln Gly Met Met Asp Ala Ser
65 70 75 80
Glu Gly Thr Asn Tyr Thr Cys Cys Lys Leu Gln Arg His Glu Trp Asn
85 90 95
Lys His Gly Trp Cys Asn Trp His Asn Ile Asp Pro Trp Ile Gln Leu
100 105 110
Met Ser Arg Thr Gln Ala Asp Leu Ala Glu Gly Pro Pro Val Lys Glu
115 120 125
Cys Ala Val Thr Cys Arg Tyr Asp Lys Asp Ala Asp Ile Asn Val Val
130 135 140
Thr Gln Ala Arg Asn Arg Pro Thr Thr Leu Thr Gly Cys Lys Lys Gly
145 150 155 160
Lys Asn Phe Ser Phe Ala Gly Thr Val Ile Glu Ser Pro Cys Asn Phe
165 170 175
Asn Val Ser Val Glu Asp Thr Leu Tyr Gly Asp His Glu Cys Gly Ser
180 185 190
Leu Leu Gln Asp Ala Ala Leu Tyr Leu Val Asp Gly Met Thr Asn Thr
195 200 205
Ile Glu Asn Ala Arg Gln Gly Ala Ala Arg Val Thr Ser Trp Leu Gly
210 215 220
Arg Gln Leu Ser Thr Ala Gly Lys Arg Leu Glu Gly Arg Ser Lys Thr
225 230 235 240
Trp Phe Gly Ala Tyr Ala Leu Ser Pro Tyr Cys Asn Val Thr Ser Lys
245 250 255
Ile Gly Tyr Ile Trp Tyr Thr Asn Asn Cys Thr
260 265
Claims (8)
1.猪瘟病毒E0蛋白抗体ELISA检测试剂盒,其特征在于,包括CSFV E0蛋白抗原,所述CSFV E0蛋白抗原氨基酸序列如SEQ ID NO.1所示:KALLAWAVIAIMLYQPVEAENITQWNLSDNGTNGIQHAMYLRGVNRSLHGIWPGKICKGVPTHLATDVELKEIQGMMDASEGTNYTCCKLQRHEWNKHGWCNWHNIDPWIQLMSRTQADLAEGPPVKECAVTCRYDKDADINVVTQARNRPTTLTGCKKGKNFSFAGTVIESPCNFNVSVEDTLYGDHECGSLLQDAALYLVDGMTNTIENARQGAARVTSWLGRQLSTAGKRLEGRSKTWFGAYALSPYCNVTSKIGYIWYTNNCT。
2.根据权利要求1所述的猪瘟病毒E0蛋白抗体ELISA检测试剂盒,其特征在于,
还包括酶标板和包被液;
所述CSFV E0蛋白抗原经包被液稀释,包被于酶标板上。
3.根据权利要求2所述的猪瘟病毒E0蛋白抗体ELISA检测试剂盒,其特征在于,
所述包被液为50mM pH7.5的Tris盐酸盐缓冲液;
所述CSFV E0蛋白抗原经包被液稀释为2μg/mL,包被于酶标板上。
4.根据权利要求3所述的猪瘟病毒E0蛋白抗体ELISA检测试剂盒,其特征在于,
还包括封闭液;
所述封闭液为质量分数10%的脱脂奶粉或质量分数1%的明胶,用于CSFV E0蛋白抗原包被后封闭。
5.根据权利要求1所述的猪瘟病毒E0蛋白抗体ELISA检测试剂盒,其特征在于,
还包括一抗稀释液;
所述一抗稀释液为质量分数1%的脱脂奶粉,按1:200稀释样品。
6.根据权利要求1所述的猪瘟病毒E0蛋白抗体ELISA检测试剂盒,其特征在于,
还包括酶标二抗和二抗稀释液;
所述酶标二抗为HRP标记山羊抗猪二抗;
所述二抗稀释液为质量分数5%的脱脂奶粉,按1:10000稀释酶标二抗。
7.根据权利要求1所述的猪瘟病毒E0蛋白抗体ELISA检测试剂盒,其特征在于,
还包括显色液和终止液。
8.根据权利要求1所述的猪瘟病毒E0蛋白抗体ELISA检测试剂盒,其特征在于,
还包括阴性对照和阳性对照。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111265613.4A CN114002426A (zh) | 2021-10-28 | 2021-10-28 | 猪瘟病毒e0蛋白抗体elisa检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111265613.4A CN114002426A (zh) | 2021-10-28 | 2021-10-28 | 猪瘟病毒e0蛋白抗体elisa检测试剂盒 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114002426A true CN114002426A (zh) | 2022-02-01 |
Family
ID=79924654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111265613.4A Pending CN114002426A (zh) | 2021-10-28 | 2021-10-28 | 猪瘟病毒e0蛋白抗体elisa检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114002426A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116165379A (zh) * | 2022-12-07 | 2023-05-26 | 浙江洪晟生物科技股份有限公司 | 一种猪瘟病毒鉴别检测试剂盒及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109182248A (zh) * | 2018-09-10 | 2019-01-11 | 青岛易邦生物工程有限公司 | 一种猪瘟病毒抗体检测elisa诊断试剂盒 |
CN109187969A (zh) * | 2018-09-19 | 2019-01-11 | 天康生物股份有限公司 | 检测猪瘟病毒抗体的免疫层析试纸、试剂盒和用途 |
CN109535233A (zh) * | 2018-12-05 | 2019-03-29 | 诺华生物科技(武汉)有限责任公司 | 猪瘟病毒嵌合型病毒样颗粒、制备方法及其应用和疫苗 |
-
2021
- 2021-10-28 CN CN202111265613.4A patent/CN114002426A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109182248A (zh) * | 2018-09-10 | 2019-01-11 | 青岛易邦生物工程有限公司 | 一种猪瘟病毒抗体检测elisa诊断试剂盒 |
CN109187969A (zh) * | 2018-09-19 | 2019-01-11 | 天康生物股份有限公司 | 检测猪瘟病毒抗体的免疫层析试纸、试剂盒和用途 |
CN109535233A (zh) * | 2018-12-05 | 2019-03-29 | 诺华生物科技(武汉)有限责任公司 | 猪瘟病毒嵌合型病毒样颗粒、制备方法及其应用和疫苗 |
Non-Patent Citations (5)
Title |
---|
MATTHIAS KONIG 等: "Classical Swine Fever Virus: Independent Induction of Protective Immunity by Two Structural Glycoproteins" * |
吴许丹 等: "检测猪瘟病毒E0抗体ELISA方法的建立与应用" * |
无: "NCBI Reference Sequence: AAM95952.1" * |
李鹏 等: "猪瘟流行毒株E0蛋白的原核表达及其间接ELISA方法的建立" * |
王旭: "检测猪瘟病毒E0抗体的间接ELISA方法建立及其初步应用" * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116165379A (zh) * | 2022-12-07 | 2023-05-26 | 浙江洪晟生物科技股份有限公司 | 一种猪瘟病毒鉴别检测试剂盒及其制备方法和应用 |
CN116165379B (zh) * | 2022-12-07 | 2023-09-05 | 浙江洪晟生物科技股份有限公司 | 一种猪瘟病毒鉴别检测试剂盒及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110105436B (zh) | 猪圆环病毒3型抗体的elisa检测试剂盒及其制备方法与应用 | |
CN111537712B (zh) | 惰性载体间接凝集试验检测系统及其应用 | |
CN104862285A (zh) | 猪流行性腹泻病毒抗体捕获elisa检测方法及应用 | |
CN114957454B (zh) | 一种抗csfv e2蛋白的纳米抗体、融合蛋白及其制备方法和应用 | |
CN111474367A (zh) | 非洲猪瘟病毒p30蛋白单克隆抗体筛选和检测用试剂盒及其制备方法 | |
CN109001450A (zh) | 一种检测鸡滑液囊支原体抗体的试剂盒及制备方法 | |
CN104730238A (zh) | 一种检测抗猪流行性腹泻病毒抗体的elisa检测试剂盒及其使用方法和用途 | |
CN107759674B (zh) | 一种牛支原体免疫相关性蛋白、含有该蛋白的检测试剂盒及其在牛支原体抗体检测中的用途 | |
CN108776225A (zh) | 猪细小病毒VLPs抗体检测试剂盒及其制备方法、应用 | |
CN110016078B (zh) | 一种基于pedv n蛋白特异性纳米抗体的阻断elisa的检测方法及其应用 | |
CN108318686B (zh) | 一种牛冠状病毒elisa检测试剂盒 | |
CN109239351B (zh) | 一种莲藕潜隐病毒双抗体夹心酶联免疫检测试剂盒及制备与检测方法 | |
CN109239341B (zh) | 一种牛溶血性曼氏杆菌抗体检测的间接elisa试剂盒及其应用 | |
CN114002426A (zh) | 猪瘟病毒e0蛋白抗体elisa检测试剂盒 | |
CN114152748A (zh) | 一种检测非洲猪瘟病毒的双抗体夹心elisa诊断试剂盒及其方法 | |
CN111796091B (zh) | 用于区分动物感染布氏杆菌或布氏杆菌菌影疫苗的试剂盒 | |
CN110568189B (zh) | 犬腺病毒1型抗体elisa检测试剂盒及其应用 | |
CN114014916B (zh) | 猪圆环病毒3型Cap重组蛋白、其编码基因及在ELISA抗体检测中的应用 | |
CN113512098B (zh) | 鉴别猪瘟病毒和牛病毒性腹泻病毒血清抗体间接elisa方法及其应用 | |
Keyvanfar et al. | Development and evaluation of an indirect capripoxvirus ELISA based on truncated P32 protein expressed in E. coli | |
CN115466317A (zh) | 基于pedv orf3重组蛋白制备的多克隆抗体及建立的间接elisa检测方法 | |
CN107664694A (zh) | 一种基于e2蛋白检测猪非典型瘟病毒抗体的elisa试剂盒 | |
CN111537736A (zh) | 一种鸡毒支原体抗体的间接elisa检测试剂盒及检测方法 | |
CN113583141A (zh) | 猪流行性腹泻病毒Nsp9蛋白、含该Nsp9蛋白的融合蛋白及其制备方法和应用 | |
CN106198974A (zh) | 一种快速检测虹鳟鱼血清中ihnv抗体的elisa检测试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220201 |